Radionuclide Peptide Cancer Therapy

Note: Supplemental materials are not guaranteed with Rental or Used book purchases.

ISBN: 9780824728878 | 0824728874
Cover: Hardcover
Copyright: 6/8/2006

Rent

(Recommended)

$195.21

Term

Due

Price

Semester

Aug 2

$195.21

*This item is part of an exclusive publisher rental program and requires an additional convenience fee. This fee will be reflected in the shopping cart.
Buy New

Usually Ships in 3-5 Business Days

$206.86
eBook

Available Instantly

Online: 180 Days

Downloadable: 180 Days

$49.48

Offering lower toxicity and higher accuracy than conventional therapies, this source offers illustrative coverage of this new method to treat tumors associated with brain, breast, lung, and neuroendocrine cancers. Accompanied by a CD offering color images, radiolabeling procedures, and tips on radiopharmceutical administration, this source will offer comprehensive and expert guidance on this burgeoning therapeutic technique.

Foreword	p. iii
Preface	p. v
Contributors	p. xiii
Peptide Structure and Analysis	p. 1
Introduction	p. 1
Peptide Conformation and Structures	p. 3
Methodologies for Peptide Design	p. 5
Methodologies for Peptide Synthesis	p. 11
Methodologies for Peptide Modifications Toward the Obtainment of a Peptide-Based Radiopharmaceutical	p. 16
Spectroscopic Studies	p. 19
Biomolecular Three-Dimensional Structures from X-Ray and Nuclear Magnetic Resonance Techniques	p. 22
References	p. 26
Radiopeptide Targeting for Tumor Therapy: Peptide Receptor Distribution	p. 31
Introduction	p. 31
Which Tumors Express Which Peptide Receptor?	p. 31
Multireceptor Targeting	p. 37
References	p. 38
Developments of Radiolabeled Peptides	p. 41
Introduction	p. 41
Background	p. 46
Somatostatin Analogs	p. 48
Cholecystokinin-B/Gastrin	p. 56
Bombesin	p. 60
Alpha Melanocyte Stimulating Hormone	p. 65
[Alpha][subscript v][Beta subscript 3] Antagonists	p. 70
Conclusion	p. 75
References	p. 76
The Labeling of Peptides with Positron-Emitting Radionuclides: The Importance of PET in Cancer Diagnosis	p. 87
Introduction	p. 87
The Different Positron-Emitting Radioisotopes	p. 88
Labeling Reactions with [Beta superscript +] Emitters	p. 93
Overview of Positron-Labeled Peptide Families Useful in Cancer Diagnosis and Therapy: Current Status and Future Perspectives	p. 104
Conclusion	p. 112
References	p. 113
Radiolabeling Dota-Peptides with [superscript 90]Y and [superscript 177]Lu to a High Specific Activity	p. 119
Radiolabeling Dota-Peptides with [superscript 90]Y and [superscript 177]Lu to a High Specific Activity	p. 119
Conclusions	p. 123
References	p. 124
Peptide Receptor Radionuclide Therapy: Preclinical Findings	p. 127
Introduction	p. 127
Octreotide	p. 128
Octreotide Analogs	p. 130
Lanreotide	p. 134
RC-160	p. 135
RGD-Octreotate	p. 136
Conclusion	p. 138
References	p. 138
Pathological Evaluation and Biochemical Characterization of Peptide Receptors Other Than Somatostatin Receptors as Potential Tumor Targets for Radionuclide Diagnosis and Therapy	p. 145
Introduction	p. 145
Methodological Aspects	p. 147
Biochemical and Functional Characterization of Peptide Receptors and Their Normal Distribution	p. 152
Assessing Peptide Receptor Expression in Human Tumors	p. 156
Co-expression of Peptide Receptors in Tumors: A New Challenge for the Pathologist	p. 159
Conclusive Remarks and Future Perspectives	p. 161
References	p. 162
Peptide Receptor Therapy with [superscript 90]Y-Dotatoc: The Emerging Experience in Chile	p. 173
Introduction	p. 173
Patient Population and Methods	p. 174
Results	p. 174
Selected Cases	p. 174
Conclusion	p. 178
References	p. 179
Therapeutic Potential of Radiolabeled Peptides: The Basel Experience	p. 181
PRRT with [superscript 90]Y-Dotatoc in Patients with Neuroendocrine Tumors and with Thyroid Cancer	p. 182
Locoregional PRRT with [superscript 90]Y-Dotatoc in Patients with Glioma	p. 201
Discussion	p. 206
References	p. 206
Somatostatin Receptor-Mediated Radionuclide Therapy for Cancer: Therapy with [superscript 90]Y-Dota-Lanreotide	p. 209
Summary	p. 209
Introduction	p. 210
Selection of Patients	p. 211
Preparation of [superscript 111]In-/[superscript 90]Y-Dota-Lanreotide	p. 212
Diagnostic and Dosimetric Evaluation	p. 212
Dose and Administration of [superscript 90]Y-Dota-Lanreotide	p. 213
Evaluation of Therapeutic Response	p. 214
Results	p. 214
Tumor Uptake of [superscript 111]In-Dota-Lanreotide Compared with Octreotide Derivates	p. 216
Drawbacks	p. 217
Conclusions	p. 218
Future Outlook	p. 218
References	p. 218
Receptor Radionuclide Therapy with [superscript 90]Y-[Dota[superscript 0]]-Tyr[superscript 3]-Octreotide ([superscript 90]Y-Dotatoc): The IEO Experience	p. 221
Introduction	p. 221
Safety Aspects	p. 223
Efficacy	p. 225
Conclusions	p. 230
References	p. 230
New Clinical Studies with [superscript 177]Lu-Labelled Somatostatin Analogs	p. 233
Perspective	p. 236
References	p. 237
Radiation Dosimetry Methods for Therapy	p. 239
Introduction	p. 239
Internal Dosimetry Methods	p. 241
Resources for Performing Calculations	p. 247
Progress in 3D Dosimetry and Treatment Planning	p. 251
Relating Observed Doses to Biological Effects	p. 253
References	p. 256
Dosimetry Applied to Peptide Radionuclide Receptor Therapy	p. 263
Introduction	p. 263
Radionuclides and Radiocompounds	p. 264
Methods for Pretherapy Dosimetry	p. 266
Dosimetric Results in PRRT Trials	p. 278
Physical and Radiobiological Factors Related to Kidney Damage 285 Practical Considerations and Conclusions	p. 292
References	p. 293
Further Reading	p. 299
Methods to Reduce Radiation Exposure to Personnel During Radiolabelling and Infusion	p. 301
Introduction	p. 301
Shielding Requirements	p. 303
Local Skin Dose	p. 303
Radiopharmaceutical Preparation: Radiation Protection in the Hot Lab	p. 304
Dose Calibrator	p. 308
Dose to Skin Due to Contamination	p. 308
Radiation Protection During the Infusion	p. 309
Systemic Infusion	p. 309
Locoregional Infusion	p. 309
Patient Hospitalization	p. 310
Conclusions and Recommendations	p. 312
References	p. 313
Regulatory Requirements for Therapy Trials	p. 315
Introduction	p. 315
Justification and Optimization in the Use of Ionizing Radiation for Medical Purposes	p. 317
Medical Trials with the Use of Ionizing Radiation	p. 318
Risk Categorization (Based on ICRP 62)	p. 320
References	p. 322
Pretargeted Peptide Delivery with Irreversible Antibody	p. 323
Introduction	p. 323
Evolution of Pretargeting Systems	p. 324
Irreversible Antibodies	p. 328
Pegylation	p. 330
Conclusions	p. 331
References	p. 333
Targeted Chemotherapy: New Approaches to Treatment of Various Cancers Based on Cytotoxic Analogs of Luteinizing Hormone-Releasing Hormone (LH-RH), Somatostatin and Bombesin	p. 337
Background	p. 337
Preclinical Studies with Cytotoxic Somatostatin Analog AN-238	p. 339
Preclinical Studies with Cytotoxic Bombesin Analog AN-215	p. 341
Clinical Remarks	p. 341
Conclusions	p. 342
References	p. 342
Index	p. 345
Table of Contents provided by Ingram. All Rights Reserved.

Please wait while the item is added to your bag...

FREE SHIPPING

Amazon no longer offers textbook rentals. We do!

Radionuclide Peptide Cancer Therapy

Summary

Table of Contents

Supplemental Materials